Alzheimer's drug prescribed 'off-label' for mild cognitive impairment could pose risk for some

Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation—the K-variant of butyrylcholinesterase, or BChE-K—donezpezil could accelerate cognitive decline.

from Dementia Big http://ift.tt/2liFIBc via alcoholic dementia

http://ift.tt/2lCPMHS